¶¶Òõ´«Ã½ÔÚÏß

A GBP9.9 million (USD12.9 million) investment from Innovate UK, backed by a further GBP8.9 million from industry, will support a major project to develop cutting-edge new treatments for cancer using lead-212 derived from used nuclear fuel.
 

EDF and Framatome have announced the launch of a feasibility study aimed at producing cobalt-60 for medical applications in one of EDF’s nuclear reactors.
 

Brazil's National Nuclear ¶¶Òõ´«Ã½ÔÚÏß Commission and China Isotope & Radiation Corporation have signed a memorandum of understanding "to ensure the continuous and stable supply of radioisotopes used in areas vital to scientific and social development".
 

Romania’s Nuclearelectrica has signed an agreement with Arabelle Solutions relating to the Cernavoda unit 1 refurbishment, and with Framatome for its medical radioisotopes project.
 

As well as working to speed up US licensing approval and commercialisation of its SOLO micro-modular reactor, Terra Innovatum Srl says its reactor can offer decentralised production of medical radioisotopes - and wants to engage with producers and distributors to bring them to market.
 

Nuclear battery developer Zeno Power is to make a "multi-million dollar" investment to get priority access to americium-241 supplies from Orano's la Hague recycling site in France.
 

The new isotope production system in Canada's Bruce unit 6 will increase the supply of the cancer-tackling lutetium-177 medical isotope.

In the rapidly evolving landscape of nuclear medicine, the integration of diagnostics and therapeutics - known as theranostics - represents a groundbreaking shift in how we approach the treatment of life-limiting conditions such as cancer. Wietse Smit, research and development manager, Urenco, looks at the potential, and the challenges, ahead.

China's first batch of the carbon-14 isotope produced at a commercial reactor was officially dispatched on 16 May from the Qinshan nuclear power plant in Zhejiang province.